Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.41 |
| ▸ | HTR2B | P41595 | 4/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 5/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.32 |
| ▸ | ATR | Q13535 | 1/20 | 0.31 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13999774 | 0.78 | SIGMAR1 (0.42) | HTR2CHTR2BHTR2ASIGMAR1HDAC1 | |
| SCHEMBL11019666 | 0.78 | SIGMAR1 (0.42) | HTR2CHTR2BHTR2ASIGMAR1HDAC1 | |
| SCHEMBL5568863 | 0.77 | HDAC1 (0.47) | HTR2CHTR2BHTR2ASIGMAR1HDAC1 | |
| SCHEMBL7649513 | 0.77 | PIM1 (0.42) | HTR2CHTR2BHTR2ASIGMAR1HDAC1 | |
| SCHEMBL7649520 | 0.77 | PIM1 (0.42) | HTR2CHTR2BHTR2ASIGMAR1HDAC1 | |
| SCHEMBL7649510 | 0.77 | PIM1 (0.42) | HTR2CHTR2BHTR2ASIGMAR1HDAC1 | |
| SCHEMBL1738842 | 0.77 | HTR2C (0.41) | HTR2CHTR2BHTR2ASIGMAR1HDAC1 | |
| SCHEMBL3434216 | 0.74 | MAPT (0.42) | HTR2CHTR2BHTR2ASIGMAR1HDAC1 | |
| SCHEMBL6802931 | 0.73 | SIGMAR1 (0.49) | HTR2CHTR2BHTR2ASIGMAR1HDAC1 | |
| SCHEMBL3557231 | 0.73 | SIGMAR1 (0.49) | HTR2CHTR2BHTR2ASIGMAR1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | HTR2C 1146/4885HTR2B 2017/4885HTR2A 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.